DK2414543T3 - Genetiske markører til risikohåndtering af atrieflimren og slagtilfælde - Google Patents
Genetiske markører til risikohåndtering af atrieflimren og slagtilfælde Download PDFInfo
- Publication number
- DK2414543T3 DK2414543T3 DK10758154.8T DK10758154T DK2414543T3 DK 2414543 T3 DK2414543 T3 DK 2414543T3 DK 10758154 T DK10758154 T DK 10758154T DK 2414543 T3 DK2414543 T3 DK 2414543T3
- Authority
- DK
- Denmark
- Prior art keywords
- risk
- markers
- allele
- marker
- stroke
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (10)
1. Fremgangsmåde til bestemmelse af en tilbøjelighed til en tilstand valgt fra gruppen bestående af: en hjertearytmi valgt blandt atrieflimren og atrieflagren, og slagtilfælde, i et menneskeligt individ, hvilken fremgangsmåde omfatter: detektering ved sekvensering og analyse af sekvensdata vedrørende mindst en polymorf markør i en prøve fra et menneskeligt individ fra en kaukasisk population, identificering af mindst en allel af mindst en polymorf markør, hvori forskellige alleler af den mindste ene polymorfe markør er associereret med forskellige tilbøjeligheder til tilstanden i mennesker, og bestemmelse af en tilbøjelighed til tilstanden ud fra sekvensdata, hvori den mindst ene polymorfe markør er valgt fra gruppen bestående af rs7193343, og markører i koblingsuligevægt med denne, hvori koblingsuligevægten mellem markører er karakteriseret ved værdier for r2 på mindste 0,8 i den kaukasiske HapMap-population.
2. Fremgangsmåden ifølge krav 1, hvori den mindst ene polymorfe markør er valgt fra gruppen bestående af rs7193343, og markører perfekt korreleret dermed (r2 = 1).
3. Fremgangsmåden ifølge krav 1 eller krav 2, hvori sekvensanalyse af den mindst ene polymorfe markør omfatter bestemmelse af tilstedeværelse eller fravær af mindst én allel af den mindste ene polymorfe markør.
4. Fremgangsmåden ifølge et hvilke som helst af de foregående krav, hvori bestemmelse af en tilbøjelighed omfatter sammenligning af sekvensdata med en database indeholdende korrelerede data mellem den mindst ene polymorfe markør og tilbøjelighed til tilstanden.
5. Fremgangsmåden ifølge krav 1 og 3-4, hvori den mindst ene polymorfe markør er valgt fra gruppen bestående af markørerne rs7193343 og rs719354.
6. Fremgangsmåden ifølge et hvilke som helst af de foregående krav, hvori den mindst ene allel er associeret med en forøget tilbøjelighed til tilstanden i mennesker.
7. Fremgangsmåden ifølge krav 6, hvori tilstedeværelsen af den mindst ene allel eller haplotype er indikativ for forøget tilbøjelighed med en relativ risiko på 1,10, mindst 1,11, mindst 1,12, mindst 1,13, mindst 1,14, mindst 1,15, mindst 1,16, mindst 1,17, mindst 1,18, mindst 1,19 eller or mindst 1,20.
8. Fremgangsmåden ifølge krav 6 eller krav 7, hvori den mindst ene allel er valgt fra gruppen bestående af T-allelen af rs7193343 og T-allelen af rs719354.
9. Apparat til bestemmelse af en genetisk indikator for en tilstand valgt fra gruppen bestående af: en hjertearytmi valgt blandt atrieflimren og atrieflagren, og slagtilfælde, i et menneskeligt individ fra en kaukasisk population, hvilket apparat omfatter: en processor; en computerlæsbar hukommelse, som har computer-eksekverbare instruktioner tilpasset til at blive eksekveret på processoren for at analysere markør- og/eller haplotype-information for mindst ét menneskeligt individ med hensyn til mindst én polymor markør valgt fra gruppen bestående af rs7193343, og markører i koblingsuligevægt med denne, hvori koblingsuligevægten er karakteriseret ved værdier for r2 på mindst 0,8 i den kaukasiske HapMap-population, og generere et output baseret på markør- eller haplotype-informationen, hvori outputtet omfatter et mål for tilbøjelighed af den mindste ene markør eller haplotype som en genetisk indikator for tilstanden hos det menneskelige individ.
10. Apparatet ifølge krav 9, hvori den mindst ene polymorfe markør er valgt fra gruppen bestående af markørerne rs7193343 og rs719354.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8813 | 2009-04-03 | ||
| PCT/IS2010/050001 WO2010113185A1 (en) | 2009-04-03 | 2010-03-30 | Genetic markers for risk management of atrial fibrillation and stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2414543T3 true DK2414543T3 (da) | 2017-01-23 |
Family
ID=42827538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10758154.8T DK2414543T3 (da) | 2009-04-03 | 2010-03-30 | Genetiske markører til risikohåndtering af atrieflimren og slagtilfælde |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8795963B2 (da) |
| EP (1) | EP2414543B1 (da) |
| CN (1) | CN102449165B (da) |
| AU (1) | AU2010231494B2 (da) |
| CA (1) | CA2757384A1 (da) |
| DK (1) | DK2414543T3 (da) |
| NZ (1) | NZ595918A (da) |
| WO (1) | WO2010113185A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011042920A1 (en) * | 2009-10-07 | 2011-04-14 | Decode Genetics Ehf | Genetic variants indicative of vascular conditions |
| US20130338012A1 (en) * | 2010-11-18 | 2013-12-19 | Illumina Inc. | Genetic risk factors of sick sinus syndrome |
| EP2683419B1 (en) | 2011-03-11 | 2018-05-09 | Vib Vzw | Molecules and methods for inhibition and detection of proteins |
| CA2886698C (en) * | 2012-11-09 | 2019-02-19 | Dirk Block | Tnt based diagnosis of paroxysmal atrial fibrillation |
| GB201404998D0 (en) * | 2014-03-20 | 2014-05-07 | Univ Birmingham | Atrial fibrillation therapy |
| CN104178571B (zh) * | 2014-08-14 | 2015-09-23 | 绍兴华因生物科技有限公司 | 遗传性心律失常致病基因体外检测试剂盒及rna探针 |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| CN107273699A (zh) * | 2017-07-07 | 2017-10-20 | 成都脉安科健生物科技有限公司 | 营养指导方案获取方法、装置及电子设备 |
| KR102368403B1 (ko) * | 2017-12-13 | 2022-02-25 | 에프. 호프만-라 로슈 아게 | 뇌졸중의 예측을 위한 순환하는 안지오포이에틴-2(Ang-2)와 인슐린-유사 성장 인자-결합 단백질 7(IGFBP7) |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| CN110777200B (zh) * | 2019-11-05 | 2020-10-16 | 天津市人民医院 | 早期诊断心房颤动用的gan基因 |
| CN111705123A (zh) * | 2020-06-19 | 2020-09-25 | 上海市第六人民医院 | 一种衰老过程中心肌纤维化的生物标志物及其检测方法和应用 |
| CN112083227B (zh) * | 2020-08-27 | 2021-05-14 | 电子科技大学 | 一种基于fpa的i/q失衡相位误差补偿方法 |
| CN113349791A (zh) * | 2021-05-31 | 2021-09-07 | 平安科技（深圳）有限公司 | 异常心电信号的检测方法、装置、设备及介质 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| EP0695941B1 (en) | 1994-06-08 | 2002-07-31 | Affymetrix, Inc. | Method and apparatus for packaging a chip |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| JP4468488B2 (ja) | 1996-05-29 | 2010-05-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 組み合せたリガーゼ検出およびポリメラーゼ連鎖反応を用いる核酸配列相違の検出 |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| WO2004028341A2 (en) * | 2001-03-19 | 2004-04-08 | Decode Genetics Ehf. | Susceptibility gene for human stroke; methods of treatment |
| CN1940086A (zh) * | 2005-09-29 | 2007-04-04 | 中国医学科学院阜外心血管病医院 | 确定患者对脑卒中遗传易感性的方法 |
| CN101096705A (zh) * | 2006-06-27 | 2008-01-02 | 安徽省生物医学研究所 | 多态性位点基因型预测心脑血管疾病发生及预后的用途、方法和试剂盒 |
| KR20150113216A (ko) * | 2006-12-05 | 2015-10-07 | 디코드 제네틱스 이에이치에프 | 심장성 부정맥의 위험 관리를 위한 유전적 마커 |
| US20090299645A1 (en) * | 2008-03-19 | 2009-12-03 | Brandon Colby | Genetic analysis |
| CN101245392B (zh) * | 2008-03-25 | 2010-12-01 | 中国医学科学院阜外心血管病医院 | 一种预测出血性脑卒中易感性的方法及试剂盒 |
-
2010
- 2010-03-30 CN CN201080022648.9A patent/CN102449165B/zh not_active Expired - Fee Related
- 2010-03-30 EP EP10758154.8A patent/EP2414543B1/en active Active
- 2010-03-30 WO PCT/IS2010/050001 patent/WO2010113185A1/en active Application Filing
- 2010-03-30 AU AU2010231494A patent/AU2010231494B2/en not_active Ceased
- 2010-03-30 CA CA2757384A patent/CA2757384A1/en not_active Abandoned
- 2010-03-30 US US13/262,550 patent/US8795963B2/en active Active
- 2010-03-30 DK DK10758154.8T patent/DK2414543T3/da active
- 2010-03-30 NZ NZ595918A patent/NZ595918A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ595918A (en) | 2013-07-26 |
| EP2414543A4 (en) | 2012-11-14 |
| WO2010113185A1 (en) | 2010-10-07 |
| CA2757384A1 (en) | 2010-10-07 |
| US20120021989A1 (en) | 2012-01-26 |
| EP2414543B1 (en) | 2016-10-12 |
| AU2010231494B2 (en) | 2016-01-07 |
| US8795963B2 (en) | 2014-08-05 |
| CN102449165B (zh) | 2014-07-09 |
| CN102449165A (zh) | 2012-05-09 |
| AU2010231494A1 (en) | 2011-11-03 |
| EP2414543A1 (en) | 2012-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2414543T3 (da) | Genetiske markører til risikohåndtering af atrieflimren og slagtilfælde | |
| DK2121979T3 (da) | Genetic markers for risk management of cardiac arrhythmia | |
| KR101374304B1 (ko) | 타입 2 당뇨병의 위험에 대한 진단 마커인 ｔｃｆ7ｌ2유전자의 유전적 변이체 | |
| AU2008256219B2 (en) | Genetic variants on Chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| DK2471954T3 (da) | Genetiske modtagelighedsvarianter forbundet med kardiovaskulære sygdomme | |
| KR20110081807A (ko) | 갑상선암의 위험도 평가를 위해 유용한 유전적 변이 | |
| US8796182B2 (en) | Genetic markers associated with risk of diabetes mellitus | |
| AU2013301606B2 (en) | Genetic markers for predicting responsiveness to FGF-18 compound | |
| EP2155907A2 (en) | Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction | |
| US20100086921A1 (en) | Genetic susceptibility variants of type 2 diabetes mellitus | |
| US20030099958A1 (en) | Diagnosis and treatment of vascular disease | |
| US20080194419A1 (en) | Genetic Association of Polymorphisms in the Atf6-Alpha Gene with Insulin Resistance Phenotypes | |
| Class et al. | Patent application title: FIBROSIS SUSCEPTIBILITY IL22RA2 GENE AND USES THEREOF Inventors: Alain Dessein (Marseille, FR) Mathieu Sertorio (Saint Ismier, FR) Laurent Argiro (Marseille, FR) Assignees: UNIVERSITE D'AIX-MARSEILLE | |
| JP2011239697A (ja) | パーキンソン病発症リスクマーカー |